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Abstract
Objective: To report a case of a preterm infant with complex meconium ileus at birth 
and cystic fibrosis.
Case description: A male infant was born by vaginal delivery at 33 weeks and 5 days of 
gestational age with respiratory distress and severe abdominal distension. The explora-
tory laparotomy in the first day of life identified meconium ileus and secondary perito-
nitis. Ileal resection and ileostomy were performed, followed by reconstruction of the 
bowel transit at 20 days of life. At 11 days of life, the first immunoreactive trypsinogen 
(IRT) was 154 ng/mL (reference value = 70), and oral pancreatic enzymes replacement 
therapy was started. After 23 days, the second IRT was 172ng/mL (reference value = 70). 
At 35 days of age he was discharged with referrals to primary care and to a special clinic 
for CF for the determination of sweat chloride. He was received in the outpatient clinic 
for neonatal screening for CF at 65 days of life presenting malnutrition and respiratory 
distress. The sweat chloride test was performed, with a positive result (126mEq/L).
Comments: This case illustrates the rapid evolution of CF in a premature patient with 
complex meconium ileus as the first clinical manifestation.
© 2015 Sociedade de Pediatria de São Paulo. Published by Elsevier Editora Ltda. All rights 
reserved.
DOI of original article: http://dx.doi.org/10.1016/j.rpped.2014.12.004 
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Manifestações precoces da fibrose cística em paciente prematuro com íleo meconial 
complexo ao nascimento
Resumo
Objetivo: Relatar o caso de um recém-nascido prematuro com íleo meconial complexo e 
fibrose cística.
Descrição do caso: Recém-nascido do sexo masculino nasceu de parto vaginal com 33 se-
manas e cinco dias de idade gestacional e apresentou desconforto respiratório e disten-
são abdominal grave. Foi submetido à laparotomia exploratória no primeiro dia de vida 
e identificado íleo meconial com peritonite secundária. Foram feitas ressecção ileal e 
ileostomia, com reconstrução do trânsito intestinal aos 20 dias de vida. Com 11 dias de 
idade, a primeira dosagem sérica de tripsina imunorreativa (TIR) foi 154ng/mL (valor 
de referência = 70) e optou-se pelo início da terapia de reposição oral de enzimas pan-
creáticas. Após 23 dias, a segunda TIR foi 172ng/mL (valor de referência = 70). Recebeu 
alta com 35 dias de vida com encaminhamentos à rede básica de saúde e ao serviço de 
referência para a detecção de fibrose cística. Foi atendido no ambulatório de triagem 
neonatal para fibrose cística aos 65 dias de vida e apresentava desnutrição e desconforto 
respiratório. O resultado do teste do cloro no suor foi positivo (126 mEq/L).
Comentários: O caso ilustra a rápida evolução da fibrose cística em um paciente prema-
turo com íleo meconial complexo como primeira manifestação clínica.
© 2015 Sociedade de Pediatria de São Paulo. Publicado por Elsevier Editora Ltda. Todos os 
direitos reservados.
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Introduction
Cystic Fibrosis (CF) is the most prevalent lethal autosomal 
recessive disorder, affecting 1:2,000 caucasians. It is caused 
by the alteration of a gene located on the long arm of chro-
mosome 7 that encodes a protein of 1,480 amino acids, the 
cystic fibrosis transmembrane conductance regulator 
(CFTR), which functions as a chloride channel on the apical 
membrane of epithelial cells.1 This alteration results in a 
change of the viscosity of secretions, with the production 
of thick mucus, leading mainly to malabsorption, loss of 
electrolytes in sweat and alteration of pulmonary secre-
tions. There are more than 1,900 known genetic mutations, 
as well as disease modifying genes.2 This phenotypic het-
erogeneity involves different clinical presentations, rang-
ing from mild to severe, which can determine a lethal out-
come. The classic presentation of CF is chronic lung disease 
(recurrent pulmonary infections), exocrine pancreatic 
insufficiency (diarrhea and malnutrition), loss of salt, and 
obstructive azoospermia syndrome.3 In cases without clini-
cal manifestations suggestive of CF in the first month of 
life, neonatal screening may lead to early detection and 
allows immediate treatment of pancreatic insufficiency, 
nutritional deficiencies and pulmonary involvement, 
improving survival and facilitating the design of treatment 
strategies.4
Less frequently, meconium ileus (MI) may be the first 
manifestation of CF in the neonatal period, occurring in 
approximately 20% of patients with pancreatic insufficien-
cy. This clinical picture is caused by obstruction of the ter-
minal ileus with thick meconium containing high amounts 
of protein. Complex MI is a severe condition, significantly 
more frequent in patients without CF of lower gestational 
age and birth weight than in patients with CF. MI is classi-
fied as complex when associated with ileal perforation.5,6 
About 80% of cases of MI are due to CF, and it would be 
ideal to perform an early sweat chloride test before 48 
hours of life, although this is not always feasible.7,8 Children 
with MI appear to have normal pulmonary function at CF 
diagnosis, with slower progression of lung disease than 
those diagnosed due to respiratory symptoms.9,10 However, 
it is currently believed that lung inflammation may occur 
early, and may even precede the onset of infection in 
infants with newly diagnosed cystic fibrosis.11
The objective of the present communication is to report 
the case of a child with complex MI who had a poor early 
evolution despite the clinical suspicion of CF.
Case description
A male infant was received in the outpatient clinic for neo-
natal screening for CF at 65 days of life. He was born by 
vaginal delivery, weighing 2,100g at 33 weeks and 5 days of 
gestational age, with Apgar scores of 6 and 9. His mother 
was a 19-year-old primigravida who had attended nine pre-
natal consultations with negative serology for vertical 
infections and normal obstetrical ultrasound. Immediately 
after birth, the infant was referred to the neonatal critical 
care unit due to early respiratory distress and severe 
abdominal distension. A plain abdominal radiograph 
revealed absence of air in the lower abdomen. The patient 
underwent exploratory laparotomy in the first day of life, 
which identified MI and secondary peritonitis due to intes-
tinal perforation. Ileal resection and ileostomy were per-
formed, followed by reconstruction of the bowel transit at 
20 days of life. He had early and late neonatal sepsis during 
the hospital stay, requiring prolonged antibiotic therapy. 
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Parenteral nutrition was gradually transitioned to infant 
formula up to a volume of 160mL/kg/day. At 11 days of life 
the result of the first immunoreactive trypsin (IRT) was 
154ng/mL, and oral pancreatic enzymes replacement ther-
apy was started (1,000U/kg/dose every 3 hours before 
feeding). After 23 days, the second IRT was 172ng/mL. At 
35 days of age he was weighing 2,040 g and was discharged 
with referrals to primary care and to a special clinic for CF 
for the determination of sweat chloride.
After 65 days of life, the sweat chloride test was per-
formed in the reference service with a positive result 
(126mEq/L). That same day, the patient was attended at 
the follow-up clinic for neonatal screening for CF. According 
to his mother, the same guidelines were maintained regard-
ing the volume of infant formula and the dosage of pancre-
atic enzymes, which she was instructed to offer mashed in 
water. He weighed 2,610 g and his length was 48cm. He had 
gained 19g/day after discharge. He had tachypnea (62 respi-
ratory cycles/minute), pallor (2/4+) and persistent dry 
cough. His chest X-ray revealed pulmonary hyperinflation 
and condensation compatible with pneumonic disease. The 
patient was hospitalized and the laboratory tests per-
formed during hospitalization are shown in Table 1. The 
C-reactive protein (CRP) test performed at admission was 
18.8mg/dL (Reference Value <0.5mg/dL by turbidimetry). 
Laboratory tests for respiratory syncytial virus, adenovirus 
and influenza, as well as blood cultures were negative. 
A pulmonary CT scan was performed on the 6th day of hos-
pital stay (Fig. 1).
An enteral diet was prescribed, with a volume of 150mL/
kg/day of semi-elemental formula at 1:25 dilution. The dose 
of pancreatic enzymes was adjusted to 5,000 U before feed-
ing, every 3 hours. A transfusion of red blood cells was per-
formed. Enteral sodium (4mEq/kg/day) and potassium 
(1mEq/kg/day) were replaced. Multivitamins (24 drops/day) 
and zinc sulfate (1mg/kg/day) were prescribed. After cul-
ture, and based on the microorganism isolated from 
the upper respiratory tract secretion (Table 1), ceftazi-
dime (200mg/kg/day), gentamicin (5mg/kg/day), and oxa-
cillin (200mg/kg/day) were prescribed. Due to ileal resec-
tion, vitamin B12 (100mcg) was administered intramuscular-
ly. On the seventh day of hospital stay, due to progressive 
worsening of the respiratory pattern, noninvasive ventilation 
(CPAP) was applied for two weeks. After stabilization of pul-
monary disease he progressed with satisfactory weight gain. 
He was discharged after 40 days, weighing 3,490 g, without 
antibiotics, with sodium replacement (adjusted to 2mEq/kg/
day) and ferrous sulfate (4mg/kg/day).
Table 1 Exams performed at the beginning and at the end of hospitalization of the patient at the referral service for CF 
management.
Laboratory test Reference values Day of hospitalization
1 2 6 35
Serum
Hb (g/dL) 10-14 6.6 9.4 8.8
Ht (%) 28-42 21 30 26
WBC (/µL) 5,000-15,000 15,000 7,300
Differential (%) (7B/5Me/2My) No immature forms
Platelets (/µL) 150-300.103 662,000 532,000 391,000
Na+ (mEq/L) 135-145 125 121 137 135
K+ (mEq/L) 3.5-5.0 3.1 3.1 4.5 4.3
Cl– (mmol/L) 98-1,107 94 92 101 105
Total Protein (g/dL) 6.0 5.2 5.7
Albumin (g/dL) 3.5 3.2 4.0
B12 Vitamin (pg/mL) 175-878 >1,000
Zinc (mcg/%) 50-120 74.5
Arterial Blood Gas
pH (mmHg) 7.35-7.45 7.45 7.43 7.35
pO2 (mmHg) 75-100 61.0 72.7 78.4
pCO2 (mmHg) 35-45 37.6 40.0 40.3
HCO3 (mmHg) 21-28 25.6 25.9 21.7
BE (mmol/L) 0- ±2 +2 +1.9 –3.0
SaO2 (%) 95-98 94.1 95 96
URT Secretion
Culture Staphylococcus 
aureus
Pseudomonas aeruginosa, 
Burkholderia cepaccia
Negative
Faecal
Steatrocrit (%) <10 — — 50 35
b, bands; me, metamyelocites; my, myelocytes; URT, upper respiratory tract.
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Discussion
It is known that the confirmation of CF may be difficult 
during the first days of life, but in the presence of meconi-
um ileus this differential diagnosis should be compulsorily 
considered. The sweat chloride test can be performed after 
48 hours of life, but more reliable results are obtained 
after the second week of life, with the patient weighing 
more than 2 kg, showing adequate hydration status and 
without significant systemic disease.12 The sweat chloride 
test is the gold standard for the diagnosis of CF; however, 
some situations may alter the results, such as dehydration, 
low weight, skin rash or a bad general condition.13,14 Despite 
the importance of an early sweat chloride test, the clinical 
status of the present patient was not appropriate for test-
ing him during the first days of life.
Cystic fibrosis transmembrane conductance regulator 
(CFTR) genetic analysis also helps the diagnosis of CF when 
it detects two known mutations.15 This exam would have 
been useful for the present patient if it had detected the 
two characteristic mutations for CF, however, the exam is 
not routinely available in our center due to its high cost. 
The nationwide Brazilian Newborn Screening Program start-
ed in 2011, although it was first implemented in 2010 in the 
state of São Paulo.16 The method of two IRT samples was 
adopted, with the first sample being collected between 3 
and 7 days of life and the second up to 30 days of life. If 
both (IRT) samples are positive (Reference Value ≥70ng/mL), 
CF is confirmed by two positive sweat chloride tests 
(Reference Value ≥60mEq/L). A sweat chloride test between 
30 and 60mEq/L is “borderline” for neonates and does not 
immediately exclude or confirm the disease.17
Although the importance of two IRTs neonatal screenings 
for CF detection, the benefit seems smaller for infants with 
meconium ileus because neonates with CF and MI may have 
low initial IRT values.18 Even if IRT levels remain elevated, 
this would simply alert to the possible presence of CF with-
out confirming the disease, because several factors increase 
the possibility of false-positive IRT values, including perina-
tal stress.19 Although low IRT values were expected for the 
present patient, the levels detected were high, supporting 
the suspicion of CF and probably also the decision of empir-
ically starting the treatment of pancreatic insufficiency 
due to CF.
Neonates with MI should receive specific treatment for 
pancreatic insufficiency while pending confirmation of CF 
by the sweat chloride test. Weight gain during hospital stay 
indicates a good response.20 Current reports state that MI is 
no longer regarded as a poor prognostic factor in patients 
with effective treatment for CF.21 The present patient was 
discharged using pancreatic enzymes, with the mother dis-
solving them in water. This procedure illustrates the impor-
tance of an early and frequent monitoring of children with 
a suspected chronic, rare and severe disease by the refer-
ence service for CF treatment, both regarding support to 
the family and the refinement of the guidelines offered, so 
that they will be closely followed. It should be emphasized 
that this type of care involves, but does not replace patient 
monitoring by a general pediatrician. The management of 
pancreatic insufficiency involves the oral ingestion of intact 
microspheres of pancreatic enzymes immediately before 
breastfeeding, ranging from 2,000 to 4,000IU lipase for 
each 120mL of formula or breastfeeding. Although less 
physiological, the calculation can also be performed using 
a dose of 1,000IU lipase/kg/meal for children younger than 
4 years, avoiding doses higher than 2,500IU/kg/meal and 
10,000IU/kg/day, which could trigger fibrosing colonopa-
thy.22
The lungs may be affected since the period of CF neona-
tal screening, with 81% of cases showing structural abnor-
malities, 45% bronchial wall thickening, and 21% lung infec-
tion.23 Cough and dyspnea in neonates and infants indicate 
the need to include CF in the list of differential diagnoses. 
Pulmonary inflammation or infection may already be pres-
ent, with Staphylococcus aureus being the microorganism 
most frequently detected, followed by Pseudomonas aeru-
A B
Figure 1 Pulmonary computer scanner images. A. Reveals several bands of atelectasis with bronchiectasis and some bronchi 
with thickened walls. B. Reveals other bronchial wall thickening, peribronchial inflammation, and extensive area of 
condensation.
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ginosa, with significant respiratory symptoms. Researchers 
observed that infants with cystic fibrosis detected by new-
born screening may have lung disease with bacterial infec-
tion since the first days of life.24,25 This is a source of con-
cern, because it is linked to early onset of bronchiectasis 
and more severe lung inflammation.
The present case report illustrates the rapid multisystem 
evolution of CF in a premature patient with complex MI as 
the first clinical manifestation. It also shows the presence 
of paradoxical results of neonatal screening (IRT/IRT) in 
patients with MI, and the difficulties of the early chloride 
sweat testing and of genotyping for CF in MI cases. 
Furthermore, it emphasizes the importance of a rapid 
referral of patients with MI and suspected CF to a team of 
experts.
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